

Aeolus Pharmaceuticals (OTCPink: AOLS)

26361 Crown Valley Parkway
Suite 150
Mission Viejo, CA 92691

Share Price	\$0.00
Volume	933.2k
Shares Outstanding	152,085,825
Market Cap	\$684.39k
52 Week High	\$0.12
52 Week Low	\$0.00

as of 04/03/2018



Overview

Aeolus Pharmaceuticals is developing a new class of broad-spectrum, catalytic-antioxidant compounds that protect healthy tissue from the damaging effects of radiation. Its first compound, AEOL 10150, is being developed, with funding by the US Department of Health and Human Services, as a medical countermeasure against chemical and radiological weapons, where its initial target indications are as a protective agent against the effects of acute radiation syndrome and delayed effects of acute radiation exposure. Aeolus' strategy is to leverage the substantial investment in toxicology, manufacturing, and preclinical and clinical studies made by US Government agencies in AEOL 10150, including the contract with BARDA valued, with options, at up to \$118.4 million, to efficiently develop the compound for use in oncology.

Management Team

John L. McManus
Chief Executive Officer

Brian Day, Ph.D.
Chief Scientific Officer

Christopher Stanley
VP, Operations

Disclaimer

Except for the historical information contained herein, the matters discussed in this document are forward-looking statements that involve risks and uncertainties, including but not limited to business conditions and the amount of growth in our industry and general economy, competitive factors, and other risks detailed from time to time in the Company's SEC reports, including but not limited to its annual reports on Form 10-K and its quarterly reports on Form 10-Q. The Company does not undertake any obligation to update forward-looking statements. All trademarks and brand names are the property of their respective companies.

Recent News

Thursday, June 08, 2017 - 10:35 AM

[Aeolus Announces FDA Fast Track Designation Granted to AEOL 10150 for Treatment of Patients With Lung Acute Radiation Syndrome Following a Radiological or Nuclear Event](#)

Monday, May 15, 2017 - 05:00 PM

[Aeolus Announces Second Quarter Financial Results for Fiscal Year 2017](#)

Thursday, March 23, 2017 - 08:00 AM

[Aeolus Receives BARDA Decision Regarding Additional Options for Lung ARS Development Contract; Files Response to Assertions Made by BARDA in the Notification](#)

Wednesday, March 15, 2017 - 09:00 AM

[AEOL 20415 Protects Lungs Against Infection in Animal Model of Cystic Fibrosis](#)

Wednesday, February 22, 2017 - 08:00 AM

[Aeolus Initiates Phase 1 Study of AEOL 10150 in Healthy Normal Volunteers](#)